Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...
Reserve mortgages — more commonly known as reverse mortgages — allow homeowners 62+ to convert home equity into cash without monthly loan payments. The loan is repaid when the homeowner sells, moves ...
Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...
Join the Tom's Guide Club for quick access. Enter your email below and we'll send confirmation, and sign you up to our newsletter.
Researchers at MIT's CSAIL published a design for Recursive Language Models (RLM), a technique for improving LLM performance on long-context tasks. RLMs use a programming environment to recursively ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...
Please provide your email address to receive an email when new articles are posted on . Patients with CLL and SLL who received pirtobrutinib had superior response than those who received ibrutinib in ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results